Efficacy of elagolix in the treatment of endometriosis.


INTRODUCTION:Much research has gone into developing medications that can be used to alleviate endometriosis-associated symptoms. In addition to already established medications, a new GnRH antagonist, elagolix, is in development. The novelty of this drug compared to other GnRH antagonists, is its nonpeptide structure, allowing it to be administered orally. Areas covered: We analyzed several Phase I, II and III clinical trials that have evaluated the safety and efficacy of this new medication. Expert opinion: Since many medications have been put on the market and have gained popularity for the treatment of endometriosis-associated symptoms, the demonstration of equality or superiority of effect, tolerability, as well as patient compliance should be assessed when introducing a new drug. While elagolix may have an advantage over established GnRH agonists, in that it does not lead to a 'flare-up' effect, it too, takes a toll on bone mineral density. Nevertheless, studies have shown that this new oral GnRH antagonist is well tolerated, and the side effects have been described as 'mild or moderate'. However, in order to examine whether elagolix can compete with or even surpass established gold-standard medical treatments in this field, further studies that directly compare elagolix to said treatments, might be necessary.


Perricos A,Wenzl R




Has Abstract


2017-09-01 00:00:00












  • Lactic acidosis related to nucleoside therapy in HIV-infected patients.

    abstract::The incidence of nucleoside analogue-related lactic acidosis has been estimated in 0.57 - 8.5 cases/1000 person years of antiretroviral therapy. The onset of lactic acidosis is usually insidious and patients complain of nausea, vomiting, abdominal pain, fatigue and weight loss. When lactate levels are high enough, a c...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Falcó V,Crespo M,Ribera E

    更新日期:2003-08-01 00:00:00

  • Current strategies for the treatment of complicated intraabdominal infections.

    abstract:INTRODUCTION:Complicated intraabdominal infections (cIAIs) are a common cause of infection-related morbidity and mortality in hospitalized patients and present many challenges unique from other serious infections. cIAIs are generally polymicrobial in nature; however, controversy exists around the pathogenicity of some ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Skrupky LP,Tellor BR,Mazuski JE

    更新日期:2013-10-01 00:00:00

  • Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections.

    abstract::Staphylococcus aureus is a bacterial pathogen responsible for a variety of serious infections and is a frequent cause of nosocomial disease. During the last 60 years, S. aureus has developed increasing in vitro resistance to virtually all antimicrobials. In contrast, vancomycin has maintained a high degree of activity...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Pope SD,Roecker AM

    更新日期:2007-06-01 00:00:00

  • Treatment of dyslipidaemia in HIV-infected persons.

    abstract::Accumulating evidence suggests that HIV-infected individuals have an increased risk of cardiovascular events. This risk seems to be at least partially mediated by dyslipidaemia, which is related to the use of highly active antiretroviral therapy (HAART). As HIV-infected individuals live longer due to HAART, their card...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Manuel O,Thiébaut R,Darioli R,Tarr PE

    更新日期:2005-08-01 00:00:00

  • TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.

    abstract::There is accumulating evidence that tumour necrosis factor (TNF) plays a major role in the pathogenesis of rheumatoid arthritis (RA). Recent biotechnological advances have allowed for the development of agents that directly target TNF, a pro-inflammatory cytokine. In the last 2 years, the US FDA and the EU's Commissio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Mikuls TR,Moreland LW

    更新日期:2001-01-01 00:00:00

  • VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.

    abstract::Angiotensin-converting enzyme inhibitors (ACE-Is) are an evidence-based treatment for patients who after myocardial infarction (MI) present with either heart failure (HF) or left ventricular systolic dysfunction, or both. An alternative could be a more complete inhibition of the renin-angiotensin system through the bl...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,随机对照试验


    authors: Maggioni AP,Fabbri G

    更新日期:2005-03-01 00:00:00

  • Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease.

    abstract:INTRODUCTION:Bronchodilators represent the mainstay of symptomatic treatment for chronic obstructive pulmonary disease (COPD). The principal bronchodilator agents are β(2)-agonists, anticholinergics and methylxanthines, used singly or in combination. Indacaterol is a novel long-acting β(2)-agonist for maintenance bronc...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章


    authors: Steiropoulos P,Papanas N,Nena E,Bouros D

    更新日期:2012-05-01 00:00:00

  • An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.

    abstract:INTRODUCTION:Phosphodiesterase type 5 inhibitors (PDE5-i) are used for the oral treatment of erectile dysfunction (ED). Since the launch of sildenafil more than 15 years ago, new molecules have become available. At present, in addition to tadalafil and vardenafil, there are three other drugs, udenafil, avanafil and mir...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Bruzziches R,Francomano D,Gareri P,Lenzi A,Aversa A

    更新日期:2013-07-01 00:00:00

  • The management of acute diarrhea in children in developed and developing areas: from evidence base to clinical practice.

    abstract:INTRODUCTION:Acute diarrhea remains a major problem in children and is associated with substantial morbidity, mortality and costs. While vaccination against rotavirus could reduce the burden of the disease, the persistent impact of intestinal infections requires effective treatment in adjunct to oral rehydration soluti...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Guarino A,Dupont C,Gorelov AV,Gottrand F,Lee JK,Lin Z,Lo Vecchio A,Nguyen TD,Salazar-Lindo E

    更新日期:2012-01-01 00:00:00

  • Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives.

    abstract:INTRODUCTION:Hodgkin lymphoma (HL) is a lymphoid malignancy with an incidence of 2 - 3/100,000/year. Young adults are most often affected. Due to the development of highly active multi-agent chemotherapy protocols and the optimization of radiotherapy (RT) fields and doses, HL has become one of the malignancies with the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Eichenauer DA,Böll B,Diehl V

    更新日期:2014-06-01 00:00:00

  • Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?

    abstract::Introduction: Multiple sclerosis (MS) is a demyelinating disease, causing axonal damage and disability. Dalfampridine (DAL) is an extended-release formulation of 4-aminopyridine (4AP) and broad-spectrum voltage-dependent potassium channel blocker that is reported to improve motor, visual and cognitive functions. Furth...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章


    authors: Foschi M,Lugaresi A

    更新日期:2019-08-01 00:00:00

  • Sorafenib in liver cancer.

    abstract:INTRODUCTION:With growing knowledge of the molecular pathway of carcinogenesis, targeted therapies have become the 'blue ocean' of cancer treatment. sorafenib is an oral multikinase inhibitor that targets Raf/mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase (ERK) (Raf/MEK/ERK) and several ty...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Woo HY,Heo J

    更新日期:2012-05-01 00:00:00

  • Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables.

    abstract:INTRODUCTION:Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disease of the central nervous system affecting both white matter and grey matter in the earliest phases of its course. The crucial role of neurodegeneration in disability progression in MS, regardless of white matter damage, has been confirm...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Pitteri M,Magliozzi R,Bajrami A,Camera V,Calabrese M

    更新日期:2018-03-01 00:00:00

  • Glatiramer acetate for the treatment of multiple sclerosis.

    abstract::Glatiramer acetate (Copaxone, Teva Pharmaceuticals Ltd) is a collection of immunomodulatory, synthetic polypeptides indicated for the treatment of relapsing-remitting multiple sclerosis (RR MS). Preclinical and clinical studies provide an evolving understanding of the mechanisms by which glatiramer acetate exerts both...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Wolinsky JS

    更新日期:2004-04-01 00:00:00

  • Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.

    abstract:INTRODUCTION:The introduction of novel agents has significantly improved multiple myeloma (MM) patient outcome during the last two decades. MM received the most drug approvals for any one malignancy during this time period, both in the United States as well as in Europe. Areas covered: Proteasome inhibitors, immunomodu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Podar K,Pecherstorfer M

    更新日期:2017-08-01 00:00:00

  • Current options for the management of postmenopausal osteoporosis.

    abstract:INTRODUCTION:Osteoporosis is a well-recognized disease with severe consequences if left untreated. The prevention of osteoporosis-associated fractures should include fall prevention, calcium supplementation and life-style advice, as well as pharmacological therapy using agents with proven antifracture efficacy. AREAS ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Lecart MP,Reginster JY

    更新日期:2011-11-01 00:00:00

  • New phosphodiesterase inhibitors in the treatment of erectile dysfunction.

    abstract::Sildenafil revolutionised the treatment of erectile dysfunction (ED) on its introduction in 1998. Not only is it effective, but is, perhaps even more importantly, an extremely acceptable manner in which to treat ED (i.e., oral pharmacotherapy), compared to the other treatments that were available at that time (e.g., i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Anderson PC,Gommersall L,Hayne D,Arya M,Patel HR

    更新日期:2004-11-01 00:00:00

  • Novelties in the multifaceted miconazole effects on skin disorders.

    abstract:BACKGROUND:Miconazole nitrate is a time-honored antifungal of the imidazole class. OBJECTIVE:To revisit the various aspects of action of the drug in a dermatologic setting. METHOD:Review of the current peer-reviewed publications. RESULTS/CONCLUSION:Miconazole essentially inhibits 14alpha-demethylase, an enzyme requi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Quatresooz P,Vroome V,Borgers M,Cauwenbergh G,Piérard GE

    更新日期:2008-08-01 00:00:00

  • Anorexia in end-stage renal disease: pathophysiology and treatment.

    abstract::Anorexia is a frequent complication of uraemic syndrome, which contributes to malnutrition in dialysis patients. Uraemic anorexia has been associated with many factors. This paper reviews the current knowledge about mechanisms responsible for uraemic anorexia, the treatments and new drugs used to control the loss of a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Aguilera A,Selgas R,Diéz JJ,Bajo MA,Codoceo R,Alvarez V

    更新日期:2001-11-01 00:00:00

  • The pharmacological management of hairy cell leukemia.

    abstract:INTRODUCTION:Hairy cell leukemia (HCL) is a B-cell lymphoid malignancy that accounts for approximately 2% of all leukemias. Treatment with purine nucleoside analogs (PNA) results in a high response rate and remains the standard of care. Long term follow-up shows that most patients relapse and require retreatment. Newer...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Ramos Perez J,Ravandi-Kashani F

    更新日期:2020-08-01 00:00:00

  • Varicella zoster: an update on current treatment options and future perspectives.

    abstract:INTRODUCTION:Varicella zoster virus is a highly contagious virus that causes a primary infection known as varicella (chickenpox) that may reactivate years later to cause herpes zoster (HZ or shingles). After shingles heal, patients may develop post-herpetic neuralgia (PHN), neuropathic pain syndrome that can cause sign...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Kim SR,Khan F,Ramirez-Fort MK,Downing C,Tyring SK

    更新日期:2014-01-01 00:00:00

  • Advances in pharmacotherapy for hyperphosphatemia in renal disease.

    abstract:INTRODUCTION:Hyperphosphatemia in chronic kidney disease (CKD) is considered as an independent risk factor for surrogate clinical end points like vascular calcification (VC) and bone disease, or hard clinical outcomes like cardiovascular events. Various treatment options are available for phosphate removal or reduction...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Spasovski G

    更新日期:2015-01-01 00:00:00

  • Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.

    abstract:INTRODUCTION:As type 2 diabetes mellitus (T2DM) advances, patients receiving basal insulin will eventually require another agent on top of their current regimen in order to achieve glycemic control. One such agent that can be administered in combination with basal insulin is the glucagon-like peptide-1 receptor agonist...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章


    authors: Forst T

    更新日期:2016-08-01 00:00:00

  • Opioids in the treatment of postoperative pain: old drugs with new options?

    abstract::New approved options with opioids in the postoperative setting may include new ways of administration, new combinations with other drugs and new opioid drugs. Newly approved devices for administration include sublingual sufentanil dispenser and transdermal iontophoretic fentanyl, with the purpose of almost mimicking t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论


    authors: Raeder J

    更新日期:2014-03-01 00:00:00

  • Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitus.

    abstract:INTRODUCTION:Combination of glibenclamide (glyburide in the U.S.) and metformin hydrochloride simultaneously addresses two different but complimentary mechanisms to improve glycemic control in type 2 diabetes. AREAS COVERED:The pharmacokinetics, efficacy, and side effect profile of the oral combination of glibenclamid...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Lamos EM,Stein SA,Davis SN

    更新日期:2012-12-01 00:00:00

  • Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.

    abstract::Poor therapeutic adherence is a major issue faced by physicians today. This paper summarizes the adherence rates with oral bisphosphonate (OBP) treatment in clinical practice and their impact on clinical outcomes. Studies systematically demonstrated that overall compliance and persistence with OBPs among osteoporotic ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Rabenda V,Hiligsmann M,Reginster JY

    更新日期:2009-10-01 00:00:00

  • Langerhans cell histiocytosis: pragmatic empirism on the road to rational cure.

    abstract::Langerhans cell histiocytosis (LCH) is a rare disease characterized by the accumulation of clonal dendritic cells in different organs. Most recent findings (e.g., activating BRAF mutations) favor the hypothesis that LCH may represent a neoplasm with varying behavior, but the ultimate pathogenesis remains to be uncover...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 评论,社论


    authors: Minkov M

    更新日期:2012-08-01 00:00:00

  • 1st International Conference on Panic Attacks: diversity of theories and treatments. september 5-8, 2003, London.

    abstract::The 1st International Conference on Psychophysiology of Panic Attacks focused on the diversity of treatments and theories in this complex condition. Experimental research topics were featured, as well as treatment strategies, case studies and patient perspectives. The conference aimed to create a strong multi-cultural...

    journal_title:Expert opinion on pharmacotherapy



    authors: Perry D

    更新日期:2004-04-01 00:00:00

  • Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.

    abstract:INTRODUCTION:In this review, the authors describe medications in phase III of clinical development for schizophrenia and schizoaffective disorder, and provide an opinion on how current treatment can be improved in the near future. AREAS COVERED:Recent (post 2013) phase III clinical trials of schizophrenia-targeted the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Garay RP,Citrome L,Samalin L,Liu CC,Thomsen MS,Correll CU,Hameg A,Llorca PM

    更新日期:2016-01-01 00:00:00

  • Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

    abstract:INTRODUCTION:Glioblastoma multiforme (GBM) is the most common high grade primary brain tumor in adults. Despite significant advances in treatment, the prognosis remains poor. Bevacizumab (BVZ) and irinotecan (CPT-11) are currently being investigated in the treatment of GBM patients. Although treatment with BVZ and irin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Jakobsen JN,Hasselbalch B,Stockhausen MT,Lassen U,Poulsen HS

    更新日期:2011-04-01 00:00:00